Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis.
Tamer Hodrob, Reem J Saad, Aya Hamdy et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the efficacy and safety of oral non-statin lipid-lowering therapies in adults with dyslipidaemia. Among 43 trials with 17,021 participants, obicetrapib 10 mg plus ezetimibe 10 mg achieved the largest LDL-C reduction of -49.15%. The findings suggest these combination therapies are effective alternatives for patients unable to tolerate statins.
Key findings
- Obicetrapib 10 mg plus ezetimibe 10 mg reduced LDL-C by -49.15%; 95% CI: -59.42 to -38.89.
- Bempedoic acid plus ezetimibe resulted in a -36.90% reduction in LDL-C; 95% CI: -44.65 to -29.15.
- Safety outcomes showed no significant increase in serious adverse events, myalgia, or elevated liver enzymes.
- Treatment discontinuation was higher with bempedoic acid 180 mg and colesevelam 3.75 g.
Why it matters
Understanding the efficacy and safety of non-statin therapies is crucial for managing dyslipidaemia, especially in patients who cannot tolerate statins or have not achieved LDL-C targets. These findings may guide treatment decisions in clinical practice.
What to keep in mind
The certainty of evidence was low to very low for many efficacy outcomes due to heterogeneity and imprecision.